Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Novel Compounds for the Treatment of Schizophrenia – A Narrative Review

Version 1 : Received: 3 July 2023 / Approved: 3 July 2023 / Online: 4 July 2023 (07:21:19 CEST)

A peer-reviewed article of this Preprint also exists.

Tsapakis, E.M.; Diakaki, K.; Miliaras, A.; Fountoulakis, K.N. Novel Compounds in the Treatment of Schizophrenia—A Selective Review. Brain Sci. 2023, 13, 1193. Tsapakis, E.M.; Diakaki, K.; Miliaras, A.; Fountoulakis, K.N. Novel Compounds in the Treatment of Schizophrenia—A Selective Review. Brain Sci. 2023, 13, 1193.

Abstract

Schizophrenia is a chronic neuropsychiatric syndrome with a significant impact on daily function and quality of life. All available guidelines suggest a combined treatment approach with pharmacologic agents and psychological interventions. However, one in three patients is a non-responder, the effect on negative and cognitive symptoms is limited, and many drug-related adverse effects complicate clinical management. As a result, discovering novel drugs for schizophrenia presents a significant challenge for psychopharmacology. This narrative review of the literature aims to present recently approved and newly discovered pharmacological substances for the treatment of schizophrenia as well as their suggested mechanism of action. We discuss seven novel drugs, three of which have been approved by the FDA (Olanzapine/Samidorphan, Lumateperone, and Pimavanserin). The rest are under clinical trial investigation (Ulotaront, CVL-231, Xanomeline/Trospium, Brilaroxazine). Additional basic and clinical research is, however, required not only to improve our understanding of the neurobiology and potential novel targets in schizophrenia treatment but also to establish modern and more effective therapeutical interventions with friendlier side-effect profiles.

Keywords

schizophrenia; schizophrenia theories; novel antipsychotics

Subject

Medicine and Pharmacology, Psychiatry and Mental Health

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.